Peptide Guides
Important
BPC-157 is not an approved medicine in any country. It holds no licence from the MHRA in the United Kingdom, the EMA in Europe, or the FDA in the United States. This guide summarises the published research on oral forms. It is not medical advice, and nothing within it constitutes a recommendation to use BPC-157. Products supplied through this site are intended for laboratory research use only.
Quick answer
- BPC-157 is unusual among peptides because it survives stomach acid, which makes an oral form possible in principle.
- Surviving the stomach is not the same as being absorbed into the blood, and no study has measured how much of a swallowed dose reaches the human bloodstream.
- The animal research used injections and direct application far more often than swallowed forms, and no results from any capsule or tablet study have ever been published.
- A 2026 pharmaceutical review found no validated oral formulation of BPC-157 exists anywhere.
What oral BPC-157 means
Oral BPC-157 is any form of the peptide taken by mouth. Capsules and tablets are the common formats sold online, and some products are liquids to be swallowed. A peptide is a short chain of amino acids, the small chemical units the body builds protein from, and BPC-157 is a peptide of 15 such units made in a laboratory. Our complete BPC-157 guide covers the compound itself.
Almost every other peptide sold for research is a freeze-dried powder intended to be dissolved, because a swallowed peptide is normally destroyed before it can do anything. BPC-157 is the one compound in this catalogue where an oral form is even worth discussing, and this guide sets out what the evidence does and does not support.
Why swallowing a peptide normally destroys it
The stomach and gut exist to break protein into pieces. Stomach acid unfolds protein chains, and digestive enzymes, the proteins that cut other molecules apart, chop the chains into single amino acids and short fragments so the body can absorb them as food. A peptide is exactly the kind of chain this system is built to cut up.
Insulin illustrates the problem. It is a peptide medicine used by millions of people, and after a century of pharmaceutical effort it is still injected, because a swallowed dose is digested like any other protein before it can act. Our guide to what peptides are explains the chemistry from the beginning.
Why BPC-157 survives the stomach
BPC-157's sequence is copied from a protective protein found in human gastric juice, the acidic fluid in the stomach. A compound derived from something that lives in stomach acid can be expected to tolerate stomach acid, and the research bears that out. The Zagreb group that discovered the compound reports it stable in human gastric juice for more than 24 hours, while most peptides break down there in minutes.1
That stability is real, and it is the entire scientific basis for oral BPC-157 products. Every capsule sold rests on it. The question that matters is what stability does and does not buy.
Which routes the animal research used
The animal studies behind BPC-157's reputation mostly did not swallow-test the compound. Across the rat research, the common routes were injection under the skin or into the abdomen, and direct application to the injured tissue. Where oral routes were used, the compound was typically dissolved in the animals' drinking water or delivered straight into the stomach through a tube.2,3
No published animal study used a capsule, and rat drinking water is not a model of a human swallowing a capsule. The oral results that do exist, including reported effects on gut injuries, sit alongside the injected results rather than replicating them route for route. Whether BPC-157 works is a separate question examined in our guide to whether BPC-157 works, and everything in that guide about the absence of controlled human trials applies to every route equally.
Why surviving the stomach is not absorption
For a swallowed compound to act anywhere beyond the gut, it must pass through the gut wall into the bloodstream intact. That step is called absorption, and the fraction of a dose that completes it is called bioavailability. Gastric stability gets a peptide to the gut wall undamaged. It says nothing about whether the peptide crosses it.
A 2026 pharmaceutical review examined BPC-157's development status in detail and found the human side of this question essentially blank. No validated oral formulation exists. Human absorption has never been measured. The compound's half-life in blood, meaning the time for half of it to disappear from circulation, was under 30 minutes in the animal work, and the review describes the gap between that short half-life and the long-lasting effects reported in animals as unexplained.2
No oral bioavailability figure for BPC-157 in humans exists in the published literature. Any percentage quoted for a capsule product has no study behind it.
BPC-157 capsules versus injection in the research
Neither route has controlled human evidence, so the comparison can only be made in animals, and there it is uneven rather than settled. Injected and directly applied routes account for most of the reported healing results across tendon, muscle and nerve injuries. Oral routes were used mainly in the gut research, where the compound acts on the tissue it is already touching and absorption into the blood matters less.
A swallowed form acting on the gut itself is the most plausible version of oral BPC-157, because it requires no absorption step at all. A swallowed form acting on a shoulder tendon requires the full chain, which is survival, absorption, circulation and arrival at the tissue, and no study in any species has traced that chain end to end.2,3
Has oral BPC-157 ever been tested in people?
A study was designed to, and its results never appeared. In December 2015 a pharmaceutical sponsor registered a Phase I study of BPC-157 tablets under the development name PCO-02, listed on the international trial registry as NCT02637284. The design was serious. It planned 42 healthy volunteers, randomised to oral 1mg BPC-157 tablets or placebo with participants, staff and assessors all blinded, measuring safety as the primary outcome and the full pharmacokinetic profile, including how much of the swallowed dose reached the blood, as the secondary outcome.
That study is exactly the measurement this whole subject is missing, and the registry record has sat frozen ever since. Its status was last verified in October 2015, and no results have ever been posted or published. A decade on, there is still no publicly available human dataset showing how much swallowed BPC-157 reaches the bloodstream, and the one study designed to produce it went silent.
What evidence would show an oral form works
Two studies would settle most of this page. A human pharmacokinetic study, meaning a study that measures the compound in blood after a swallowed dose, would establish whether meaningful absorption happens at all. A controlled human trial using an oral form would establish whether it does anything. The 2015 registration shows the first was planned once, and neither has ever been published.2
Until then, the honest position on oral BPC-157 has three parts. The gastric stability is demonstrated. The absorption is unmeasured. The effects in humans are untested by any route.
Common questions about oral BPC-157
Do BPC-157 capsules work?
Unknown. No controlled human trial has tested BPC-157 in any form, and no study in any species has tested capsules. The gastric stability that makes capsules plausible is demonstrated, and the absorption and effect that would make them work are not.
Is oral BPC-157 as effective as injection?
No study has compared them in humans, because no human trial exists for either route. In animals, the injected and directly applied routes account for most of the reported results, and the oral results concentrate in gut research where absorption into the blood is not required.
Does stomach acid destroy BPC-157?
The published research says no. The compound is reported stable in human gastric juice for more than 24 hours, which is exceptional for a peptide and is the reason oral forms are discussed at all.1
What is the right oral dose of BPC-157?
No human data exists to define one. No human pharmacokinetic study has measured absorption of a swallowed dose, so any figure attached to a capsule product is not derived from human evidence.
Specification and supply
We supply BPC-157 as freeze-dried (lyophilised) powder in sealed vials for laboratory research, purity-tested by HPLC with identity confirmed by mass spectrometry and a dated certificate of analysis published per batch. We do not sell capsules or tablets. Our guide to reconstituting peptides covers how laboratory solutions are prepared from powder. Research-grade BPC-157 is listed with its batch documentation.
Supplied for laboratory research use only. Not for human consumption.
References
- Sikiric P, Sever M, Krezic I, et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology. 2024. DOI
- Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics. 2026. DOI
- Yuan C, Demers A, Silva-Ortiz V, et al. From regeneration to analgesia: the role of BPC-157 in tissue repair and pain management. Int J Mol Sci. 2026. DOI